← All trials
NCT04894825
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 11, 2021
- Primary completion
- Jun 30, 2023
- Completion date
- Dec 30, 2023
- First posted
- May 20, 2021
- Last posted
- Aug 18, 2021
- Enrollment
- 152
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- FutureGen Biopharmaceutical (Beijing) Co., LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.